Targeted liposomal drug delivery systems for the treatment of B cell malignancies

Journal of Drug Targeting

Volumn 22, Issue 5, 2014, Pages 372-386

  Mittal, Nivesh K ^a   Bhattacharjee, Himanshu ^a   Mandal, Bivash ^a   Balabathula, Pavan ^a   Thoma, Laura A ^a   Wood, George C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Conjugation; Doxorubicin; Epitope; EPR; Monoclonal antibody; Receptor mediated endocytosis; Stealth; Vincristine

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD74 ANTIGEN; CYCLOPHOSPHAMIDE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IMMUNOLIPOSOME; INOTUZUMAB OZOGAMICIN; MACROGOL 2000; NORCANTHARIDIN; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; LIPOSOME; NANOPARTICLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; ENDOCYTOSIS; FOLLICULAR LYMPHOMA; GENE OVEREXPRESSION; HUMAN; LIPOSOMAL DELIVERY; LYMPHOCYTOMA; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, B-CELL; LIPOSOMES; LYMPHOMA, B-CELL; NANOPARTICLES;

EID: 84901040351     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.878942     Document Type: Review

References (100)

1. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59
2. Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989;63: 604-12
3. Zhang L, Gu F, Chan J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2007;83:761-9
4. Sahoo S, Parveen S, Panda J. The present and future of nanotechnology in human health care. Nanomed: Nanotechnol Biol Med 2007;3:20-31
5. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615-26
6. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010;128:324-35
7. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230-4
8. Molema G. Drug targeting: basic concepts and novel advances. In: Molema G, Meijer DKF, eds. Drug targeting: organ-specific strategies. Vol. 12. Weinheim: Wiley-VCH Verlag GmbH
9. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
10. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007;2:567-83
11. Omura S, Tanaka H, Oiwa R, et al. New antitumor antibiotics, OS- 4742 A 1, A 2, B 1 and B 2 produced by a strain of Streptomyces. J Antibiotics 1977;30:908-16
12. Rinehart J, Lewis RP, Balcerzak SP Adriamycin cardiotoxicity in man. Ann Intern Med 1974;81:475-8
13. Thierry AR, Vige D, Coughlin SS, et al. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 1993; 7:572-9
14. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631-51
15. Harris N, Jaffe E, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69-86
16. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press 2008
17. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11
18. Society. Leukemia and lymphoma. White Plains (NY): Facts Spring 2013
19. Leonard B. Leukemia: a research report. Darby (PA): Diane Pub Co 1998
20. Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev 2012;38:673-88
21. Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012;38:473-83
22. Marchese VG, Morris GS, Gilchrist L, et al. Screening for chemotherapy adverse late effects. Topics Geriat Rehabil 2011; 27:234-43
23. Gupta S, Kanodia AK. Biological response modifiers in cancer therapy. Natl Med J India 2002;15:202-7
24. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-26
25. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
26. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44
27. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007;2:751-60
28. Dijoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242-9
29. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunol 2002;3: 991-8
30. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4
31. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Rev Cancer 2002;2:750-63
32. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Rel 2008;126:50-8
33. Loomis K, Smith B, Feng Y, et al. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Experiment Molec Pathol 2010;88:238-49
34. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10:2530-7
35. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Control Rel 2006;115:251-8
36. Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011; 3:1-11
37. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Rel 2010;148:135-46
38. Hirsjärvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 2011;8: 188-96
39. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
40. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008;3:703-17
41. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-64
42. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-18
43. Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 1979;14:81-7
44. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001;46:169-85
45. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel2000;65:271-84
46. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9
47. Düzgünes N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 1999;40:3-18
48. Xiao K, Luo J, Li Y, et al. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Rel 2011;155:272-81
49. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14: 529-37
50. L. D. Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320-30
51. de Menezes DEL, Kirchmeier MJ, Gagne JF, et al. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J Liposome Res 1999;9: 199-228
52. Ishida T, Kirchmeier MJ, Moase EH, et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001; 1515:144-58
53. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004;10: 1100-11
54. Allen TM, Mumbengegwi DR, Charrois GJR. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-73
55. Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999;43:1-7
56. Bhattacharjee H, Balabathula P, Wood GC. Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: a review. Therapeutic Deliv 2010;1:713-34
57. Rodriguez M, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer 2009;115: 3475-82
58. Sarris AH, Cabanillas F, Logan PM, et al. Compositions and methods for treating lymphoma. Google Patents 2004
59. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000;11:69-72
60. Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 2002;50:6-8
61. Wetzler M, Thomas DA, Wang ES, et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leukemia 2013;13:430-4
62. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65: 36-48
63. Chang H, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 2012;7:49-60
64. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta - Biomembranes 1993;1151:201-15
65. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta (BBA) -Biomembranes 2001;1513:207-16
66. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5
67. Benita S. Microencapsulation: methods and industrial applications. Informa Health 2006;158:123-48
68. Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta (BBA)-Biomembranes 2004;1663: 167-77
69. Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000;1466:205-20
70. Mayer LD, Nayar R, Thies RL, et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1994;33:17-24
71. Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cellular Molecr Biol Lett 2002;7:217-19
72. Zhang J, Tang Y, Qian B, Sheng H. Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8. J Huazhong Univ Sci Technol - Med Sci 2010;30:240-7
73. Kirchmeier MJ, Ishida T, Chevrette J, Allen TM. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Liposome Res 2001;11:15-29
74. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009;71:431-44
75. Powell LD, Varki A. The oligosaccharide binding specificities of CD22b, a sialic acid-specific lectin of B cells. J Biol Chem 1994; 269:10628-36
76. Chen WC, Completo GC, Sigal DS, et al. In vivo targeting of Bcell lymphoma with glycan ligands of CD22. Blood 2010;115: 4778-86
77. O'Donnell RT, Martin SM, Ma Y, et al. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Investigat New Drugs 2010;28:260-7
78. Sakakibara T, Chen FA, Kida H, et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drugcontaining conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996;56: 3743-6
79. Tuscano JM, Martin SM, Ma Y, et al. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res 2010;16:2760-8
80. Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2- specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents. J Liposome Res 2008;18:293-307
81. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008;68:6300-5
82. Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Rel 2004;94:155-61
83. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007;104:13408-13
84. Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008;283: 2784-92
85. Hertlein E, Triantafillou G, Sass EJ, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010; 116:2554-8
86. Mao Y, Triantafillou G, Hertlein E, et al. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res 2013;19: 347-56
87. Golay JT, Clark EA, Beverley PCL. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985;135:3795-801
88. Bofill M, Janossy G, Janossa M. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985;134:1531-8
89. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti- HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75
90. Allen TM, Sapra P, Moase E, et al. Adventures in targeting. J Liposome Res 2002;12:5-12
91. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998;56: 747-56
92. Lothstein L, Rodrigues PJ, Sweatman TW, Israel M. Cytotoxicity and intracellular biotransformation of N- enzyladriamycin-14- valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anti-Cancer Drugs 1998;9:58-66
93. Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: cytoplasmic versus nuclear - A fork in the road. Drug Resis Updates 2001;4:169-77
94. Lothstein L, Savranskaya L, Barrett CM, et al. N-benzyladriamycin- 14-valerate (AD 198) activates protein kinase C-d holoenzymeo trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx. Anti-Cancer Drugs 2006;17:495-502
95. Ganapathi R, Grabowski D, Sweatman TW, et al. N-benzyladriamycin- 14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. Br J Cancer 1989;60: 819-26
96. Sugaya K, Alvarez A, Bushnev S, Avgeropoulos NG. Therapy targeting cancer stem cells. US Patent 20,110,313,229, 2011
97. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31:196-205
98. Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leukemia Lymphoma 2000;38: 91-101
99. Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005;23:1418-23
100. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49